Bottle Label 75 mg (71610 0527 60)
Clopidogrel Tablet, Film Coated
Product Images NDC 71610-527
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 71610-527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
Figure3.jpg (Figure3)
Figure3b.jpg (Figure3b)
The text seems to be a table showing the Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study. It includes subgroups and corresponding N, Clopidogrel, and Placebo values, as well as Favors Clopidogrel and Favors Placebo values. Therefore, it is a part of a statistical or medical research report.*
Figure6.jpg (Figure6)
This is a statistical figure from a study called COMMIT that evaluated the effects of adding clopidogrel to aspirin on the combined primary endpoint across baseline and concomitant medication subgroups. The data shows the subgroup, number of individuals (N), the number and percentage of individuals who received clopidogrel and the number of individuals who favored placebo. Additionally, there is an odds ratio for each sub-group (except for Overall).*
Figure7.jpg (Figure7)
The figure shows the cumulative event rate of fatal or non-fatal vascular events in the CAPRIE study. The x-axis represents the months of follow-up, the y-axis shows the cumulative event rate expressed as a percentage, and the line graph compares the event rate for clopidogrel to a control group. The figure suggests that clopidogrel may have a statistically significant benefit in reducing vascular events compared to the control group.*
Figure8.jpg (Figure8)
Clopiodgrel-01.jpg (Clopiodgrel 01)
Figure-01.jpg (Figure 01)
Figure 1 shows the exposure to Clopidogrel active metabolite after taking multiple doses of Clopidogrel 75mg alone or with Proton Pump Inhibitors (PPIs). The co-administered PPI effect on active metabolite AUC is displayed in mean and 90% confidence interval. The text provides specific details about the impact of different PPIs, including Dextansoprazole, Lansoprazole, Pastoprazole, and Omeprazole on active metabolite AUC. The figure also highlights the change relative to Clopidogrel administered alone.*
Figure2.jpg (Figure2)
The figure shows the cumulative event rate in percentage for cardiovascular death, myocardial infarction, and stroke during the CURE study. The study compares the effect of "placebo (+ aspirin)" versus "clopidogrel (+ aspirin)" over a period of twelve months of follow-up. Other standard therapies were also used as needed. The combination of clopidogrel and aspirin showed a statistically significant lower incidence of cardiovascular death, myocardial infarction, and stroke compared to the placebo and aspirin combination.*
Figure4.jpg (Figure4)
Not available.*
Figure5.jpg (Figure5)
The figure 5 from the COMMIT study presents the cumulative event rates for the combined endpoint of re-infarction, stroke or death. The placebo group had 10.1% of events, while the clopidogrel group had 8.2%, resulting in a 9% proportional risk reduction with a confidence interval ranging from 5%-0.002%. The endpoint events occurred before the first discharge, with the graph showing the cumulative events up to 28 days after randomization. All treated patients received aspirin.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
